Epigral to raise funds up to Rs 400 crore

04 Aug 2025 Evaluate

Epigral has received approval to raise funds up to Rs 400 crore by way of issuance of non-convertible debentures (NCDs), bonds and/or other debt securities etc. through permissible mode within the borrowing limits of the company, in one or more tranches / series. The board of directors of the company in their meeting held on August 2, 2025, have approved the same.

Epigral is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.

Epigral Share Price

1468.90 -7.60 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
BASF India 4039.90
Tata Chemicals 773.85
SRF 2886.20
Pidilite Inds. 1474.70
Deepak Nitrite 1565.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×